Global Antifungal Drugs Market, Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), Indication (Dermatophytosis, Aspergillosis, Candidiasis, Others), Dosage (Tablet, Ointment, Cream, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) - Industry Trends and Forecast to 2031.
Antifungal Drugs Market Analysis and Size
The antifungal drugs market refers to the pharmaceutical industry segment that produces and sells medications specifically designed to treat fungal infections. Fungal infections can affect various parts of the body, including the skin, nails, respiratory system, and internal organs. These infections can range from mild and superficial conditions to severe and life-threatening diseases, particularly in individuals with compromised immune systems. Antifungal drugs work by inhibiting the growth and reproduction of fungi, either by targeting the fungal cell membrane and cell wall or interfering with essential cellular processes. There are different classes of antifungal drugs, and their selection depends on the type and severity of the fungal infection.
Data Bridge Market Research analyzes that the global antifungal drugs market, which was USD 15,835.50 Million in 2023, is likely to reach USD 20,852.33 Million by 2031 and is expected to undergo a CAGR of 3.5% during the forecast period. “Hospitals” dominates the end user segment of the market due to the growing prevalence of infectious diseases.
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), Indication (Dermatophytosis, Aspergillosis, Candidiasis, Others), Dosage (Tablet, Ointment, Cream, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East & Africa
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Gilead Sciences, Inc. (U.S.), Apotex Inc. (Canada), Amneal Pharmaceuticals LLC. (U.S.), Zydus Cadila (India), Aurobindo Pharma (India), Cipla Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Dr. Reddy's Laboratories Ltd. (India), WOCKHARDT (India), Bausch Health Companies Inc. (Canada), Lannett (U.S.), Torrent Pharmaceuticals Ltd. (India)
|
|
Market Opportunities
|
|
Market Definition
Antifungal drugs are medications designed to treat fungal infections. Fungal infections can affect various parts of the body, including the skin, nails, respiratory tract, and internal organs. These infections can range from mild to severe and may require different types of antifungal medications for effective treatment. Antifungal drugs play a crucial role in treating a wide range of fungal infections, including but not limited to athlete's foot, ringworm, candidiasis, and more severe systemic infections. Individuals with compromised immune systems, such as those undergoing organ transplants or cancer treatment, are more susceptible to fungal infections. Antifungal drugs are essential in preventing and treating these infections in such vulnerable populations.
Global Antifungal Drugs Market Dynamics
Drivers
- Rise in the incidences of fungal infections
The rising incidences of fungal and nosocomial infections are a primary driver of the growth of the antifungal drugs market. Antifungal agents are effective against systemic and superficial infections which are attained from exposure to contaminated surfaces in hospitals or humid conditions.
- Increasing investment for healthcare infrastructure
Enhanced healthcare infrastructure often leads to better diagnostic facilities. Improved diagnostic capabilities can result in more accurate and timely identification of fungal infections, allowing for prompt and targeted treatment with antifungal drugs. Availability of advanced medical facilities may encourage individuals to seek medical attention for fungal infections, increasing the overall patient pool for antifungal drugs.
Opportunity
- Advancements in Antifungal Drug Development
Ongoing research and development in the field of antifungal drugs present opportunities for the introduction of novel and more potent medications. Innovations in drug formulations, delivery mechanisms, and therapeutic targets can improve treatment outcomes and patient compliance. Pharmaceutical companies investing in R&D can capitalize on opportunities to bring innovative antifungal drugs to the market. Breakthroughs in drug development, including the discovery of new drug targets and formulations with improved efficacy and safety profiles, can lead to a competitive advantage in the market.
Restraint/Challenge
- Lack of Awareness and Under diagnosis
Fungal infections are often underdiagnosed due to a lack of awareness among healthcare professionals and the general public. This can result in delayed or inadequate treatment. Insufficient awareness about the prevalence and consequences of fungal infections may lead to delayed diagnosis and treatment. This restraint underscores the importance of educational initiatives to increase awareness and improve diagnostic practices.
Recent Development
- In June 2021, Mankind Pharma had announced the launch of drug named Posaconazole Gastro. They are the resistant tablets which are used for the treatment of black fungus. It is found to be a safer as well as effective drug of choice for the management of disease. This drug had received approval from Drug Controller General of India (DCGI)
Global Antifungal Drugs Market Scope
The antifungal drugs market is segmented on the basis of drug class, indication, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Azoles
- Echinocandins
- Polyenes
- Allylamines
- Others
Indication
- Dermatophytosis
- Aspergillosis
- Candidiasis
- Others
Dosage
- Tablet
- Ointment
- Cream
- Others
Route of Administration
- Oral
- Topical
- Others
End Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Antifungal Drugs Market Regional Analysis/Insights
The antifungal drugs market is analyzed and market size insights and trends are provided by country, drug class, indication, dosage, route of administration, end users, and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia- Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and rest of Middle East & Africa.
North America is expected to dominate the market due to the presence of advanced healthcare infrastructure.
Asia-Pacific is the fastest growing region in the market due to rising prevalence of infectious diseases.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The antifungal drugs market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the antifungal drugs market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the antifungal drugs market.
Competitive Landscape and Antifungal Drugs Market Share Analysis
The antifungal drugs market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the antifungal drugs market.
Some of the major players operating in the antifungal drugs market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Gilead Sciences, Inc. (U.S.)
- Apotex Inc. (Canada)
- Amneal Pharmaceuticals LLC. (U.S.)
- Zydus Cadila (India)
- Aurobindo Pharma (India)
- Cipla Inc. (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Dr. Reddy's Laboratories Ltd. (India)
- WOCKHARDT (India)
- Bausch Health Companies Inc. (Canada)
- Lannett (U.S.)
- Torrent Pharmaceuticals Ltd. (India)
SKU-